Hepatitis B reactivation and immune check point inhibitors.
Fiche publication
Date publication
septembre 2020
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLET Pierre
Tous les auteurs :
Godbert B, Petitpain N, Lopez A, Nisse YE, Gillet P
Lien Pubmed
Résumé
Liver toxicity during immune checkpoint inhibitor treatment is mostly due to immune mediated hepatitis. Viral hepatitis, as well as auto-immune or metabolic hepatitis, are considered as exclusion criteria for ICI induced immune hepatitis diagnosis. However, considering the high prevalence of viral hepatitis B infection and the increasing prescription of immune checkpoint inhibitors, their use in patients with HBV chronic viral infection may be common, even more if patients are treated for hepatocellular carcinoma. Few clinical studies directly deal with the risk of HBV reactivation during ICI therapy and real-life data is currently based on five reported cases of HBV reactivation, one with fatal outcome. In this review, we summarize the current available clinical information about HBV reactivation risk during ICI treatment, its hypothetic mechanism, and propose practical recommendations about verifying and monitoring HBV status throughout the treatment.
Mots clés
Case report, Fulminant hepatitis, Immune checkpoint inhibitors, Reactivation, Viral hepatitis
Référence
Dig Liver Dis. 2020 Sep 10;: